Brooke Wietharn

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study

Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida et al. · Hepatology · 2022 · 234 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +11

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D’Alessio et al. · European Journal of Cancer · 2022 · 112 citations · Full text

Medicine, Oncology, Pharmacology +6

Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

Ciro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi et al. · Journal of Hepatology · 2023 · 63 citations · Full text

Medicine, Immunology, Oncology +17

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

Mathew Vithayathil, Antonio D’Alessio, Claudia Angela Maria Fulgenzi et al. · Liver International · 2022 · 38 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

Lorenz Balcar, Bernhard Scheiner, Claudia Angela Maria Fulgenzi et al. · JHEP Reports · 2023 · 26 citations · Full text

Life Sciences, Immunology, Oncology +17